A Phase II study suggests immune-related expression signatures and other immune markers may help find metastatic prostate cancer cases with better checkpoint blockade response.
Researchers found that TP53 mutations correlated with improved disease-free survival and overall survival in pancreatic cancer patients treated with gemcitabine following surgical resection.
A study evaluated data from a Phase I/II trial of Piqray combined with an aromatase inhibitor to find mechanisms of resistance hindering clinical benefit from the therapy.
HER2-targeted bispecific antibody ZW25 will be used in combination with other drugs for HER2-positive breast cancer and gastroesophageal adenocarcinoma.
